Matthew J Frank

7PUBLICATIONS
69CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Autoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Mar 19, 2026
Early steroid and anakinra use to manage axicabtagene ciloleucel toxicity reduces the total duration of CRS and ICANS.

William Lee Wang, Dasom Lee, Edna Cheung

|Mar 04, 2026
How I treat HLH-like toxicities after immune effector cell therapy.

William T Johnson, Kevin O McNerney, Matthew J Frank

|Dec 18, 2025
Clinical and Cytokine Features of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.

Hrishikesh K Srinagesh, Anne Marijn Kramer, John H Baird

|Jan 08, 2025
Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL.

Yi-Jiun Su, Anne Marijn Kramer, Mark P Hamilton

|Feb 08, 2023
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.

Yucai Wang, Preetesh Jain, Frederick L Locke

|Jul 27, 2022
CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse.

Khoan Vu, Matthew J Frank

Pageof 2

Frequent Collaborators

5 joint publications

Saurabh Dahiya

5 joint publications

David B Miklos

3 joint publications

Crystal L Mackall

2 joint publications

Neha Agarwal